Research programme: niacin receptor agonists - Arena Pharmaceuticals/Merck & Co

Drug Profile

Research programme: niacin receptor agonists - Arena Pharmaceuticals/Merck & Co

Latest Information Update: 24 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Merck & Co
  • Class Anthranilic acids; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; GPR109A receptor agonists; GPR109B receptor agonists; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 24 Dec 2009 Discontinued - Preclinical for Atherosclerosis in USA (PO)
  • 20 Aug 2009 Pharmacodynamics data from a Preclinical trial in Atherosclerosis presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
  • 20 Feb 2009 Preclinical development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top